Effect of prebiotics on intestinal transit and lipid profile of patients with Pre-Dialytic chronic kidney disease

• Grant number: 17/03436-5
• Support Opportunities: Regular Research Grants
• Start date: September 01, 2017
• End date: February 29, 2020
• Field of knowledge: Health Sciences - Nutrition
• Principal Investigator: Marina Nogueira Berbel Bufarah
• Grantee: Marina Nogueira Berbel Bufarah
• Host Institution: Hospital das Clínicas. Faculdade de Medicina (FMB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil
• Associated researchers: André Luís Balbi
• Associated scholarship(s): 18/03466-4 - Effect of prebiotics on intestinal transit and lipid profile of patients with pre-dialytic chronic renal disease, BP.TT

Abstract

Chronic kidney disease (CKD) is a serious public health problem, has a progressive character and is associated with high morbidity and mortality. In both Brazil and the world, diabetes mellitus (DM) and systemic arterial hypertension (SAH) are the main causes of CKD, and chronic kidney individuals have a high prevalence of CVD, because they have several risk factors of cardiovascular disease, one of them being atherosclerotic disease. According to a study conducted in patients with CKD on hemodialysis (HD), dyslipidemia and uremia act as important predictors of atheroma formation and consequently increased risk of CVD. The increase in the consumption of dietary fibers, known as prebiotics, represents an alternative for the improvement of the lipid profile in these individuals. Chronic constipation is also a frequent condition in patients at all stages of CKD. Considering an option for the treatment of chronic constipation in this population, the use of prebiotics may play a positive role in the improvement of this condition. Thus, regular use of prebiotics may represent a therapeutic strategy both for the reduction of constipation and for the improvement of the lipid profile in these patients. The present work aims to identify the effect of prebiotics on intestinal transit and on the lipid profile of patients with CKD in the predialytic phase. In this randomized clinical trial, the objective is evaluate 62 patientsin stage V of CKD with a diagnosis of chronic intestinal constipation according to the criteria of Rome III. 31 individuals from the placebo group and 31 from the intervention group will be followed up at the Pre- Dialysis Unit of the Clinical Hospital of Botucatu Medical College. Patients will be divided into groups (control x intervention) through a random and will receive dietary orientations aimed at improving intestinal constipation. The control group will receive 10g of carbohydrate module as placebo and the intervention group will receive 10g of prebiotics, both diluted in 150ml of filtered water 1x per day in the morning for 60 consecutive days. An initial and two subsequente valuations will be performed within a period of 30 days, composed of clinical, nutritional and biochemical parameters. The presentation of the data will be performed through descriptive statistics of position and variability and the results of hypothesis tests discussed at the 5% level of significance. (AU)